UroGen shareholders approve 2.75M share increase under 2017 equity plan and new compensation policy

UroGen Pharma Ltd.

Shareholders approved amendment to 2017 Equity Incentive Plan, authorizing 2,750,000 additional ordinary shares.
Shareholders approved Amended and Restated Non-Employee Director and Officer Compensation Policy.
All seven director nominees elected: Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Leana Wen, Daniel Wildman.
Advisory vote on executive compensation approved (18.85M for); one-year frequency for future say-on-pay votes selected.
PricewaterhouseCoopers LLP ratified as independent auditor with 32.9M votes in favor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.